01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; biological preparations,
other than for medical or veterinary purposes; biochemical
preparations for scientific purposes; diagnostic reagents
for scientific or research use; reagents for use in
scientific apparatus for chemical or biological analysis;
chemical preparations for analyses in laboratories, other
than for medical or veterinary purposes; nucleic acids for
scientific purposes; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology; enzymes
for scientific purposes; chemical reagents for use in
genetic research.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; biological preparations,
other than for medical or veterinary purposes; biochemical
preparations for scientific purposes; diagnostic reagents
for scientific or research use; reagents for use in
scientific apparatus for chemical or biological analysis;
chemical preparations for analyses in laboratories, other
than for medical or veterinary purposes; nucleic acids for
scientific purposes; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology; enzymes
for scientific purposes; chemical reagents for use in
genetic research.
3.
BMP10 FOR ASSESSING RIGHT HEART FUNCTION IN PATIENTS WITH HEART VALVE DISEASES
The present invention concerns the field of diagnostics. In particular. It relates to a method for assessing a heart valve disease or disorder comprising the steps of a) determining the amount of a BMPlO-type peptide in a sample of said subject, and b) comparing the amount determined in step a) to a reference, whereby the heart valve disease or disorder is assessed. Further, the invention concerns computer-implemented methods of the aforementioned methods as well as devices and kits for carrying out said methods. Yet, the present invention contemplates the general use of a BMPlO-type peptide in a sample of a subject or a detection agent for a BMPlO-type peptide to be applied in said sample for assessing a heart valve disease or disorder.
The disclosure relates to the production of highly pure N,N-diisopropylphosphoramidite compounds, such as 6-bromohexyl 2-cyanoethyl N,N-diisopropylphosphoramidite, and highly pure starting material used therein, such as 6-bromohexan-1-ol. The resulting N,N- diisopropylphosphoramidite compounds are useful, for example, for the improved preparation of expandable nucleotide triphosphates (XNTPs) for use in sequencing by expansion.
The present invention relates to a method for self-monitoring a woman being at risk of developing or having preeclampsia, an electronic consumer device configured for use in the method, a computer program and a medical test-kit adapted for the use in the method.
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Research in the field of artificial intelligence; Computer software design; Computer software development; Medical research; Medical research laboratory services; Research and development in the pharmaceutical and biotechnology fields; Information technology services for the pharmaceutical and healthcare industries; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research for medical purposes in the area of cancerous diseases; Scientific laboratory services; Consultancy in the field of pharmaceutical research; Medical research in the field of pathology; Providing temporary use of online non-downloadable software for accessing and using a cloud computing network; Analytic laboratory services. Medical testing for diagnostic and treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories.
7.
SAMPLE-PROCESSING DEVICE AND METHOD FOR MAGNETIC BEAD-BASED SAMPLE PROCESSING
Sample-processing device (100) for magnetic bead-based sample processing, the sample-processing device (100) comprises: A magnetic bead attraction element (10) comprising at least one first magnet section (11a) and at least one second magnet section (12a) being oriented at an angle of 90° < α < 180° with respect to the at least one first magnet section (11a); and A test tube-receiving mechanism (13) for receiving at least one test tube (14) with a main tube wall section (15) and a tapered bottom wall section (16) for containing a sample liquid (17) with magnetic beads (18), wherein the magnetic bead attraction element (10) and the test tube-receiving mechanism (13) are at least partially movably arranged relative to each other between: a first bead collection configuration (A), in which the magnetic bead attraction element (10) is positioned with respect to the test tube (14), when being received by the test tube-receiving mechanism (13), such that the at least one first magnet section (11a) overlaps with at least a portion of the main tube wall section (15) and the at least one second magnet section (12a) overlaps with at least a portion of the tapered bottom wall section (16); and a second bead collection configuration (B), in which the magnetic bead attraction element (10) is positioned with respect to the test tube (14) when being received by the test tube-receiving mechanism (13), such that the at least one first magnet section (11a) overlaps with at least a portion of the tapered bottom wall section (16).
Computer-implemented methods for analysing multimodal data are described. A computer-implemented method comprises generating an output data set by processing an input data set comprising data from one or more of a set of at least three modalities, using a machine learning model comprising a transitive and commutative machine-learning model. Related methods, products and systems are described.
A device for sensing biomolecules, the device including a first layer having a first surface energy configured for binding with particular types of complexes of tethers, target biomolecules, and magnetic nanoparticles. A second layer is positioned on the first layer, the second layer having a second surface energy substantially inert to the tethers, target biomolecules, and magnetic nanoparticles of the complexes. One or more nanowells are formed within the second layer, each exposing a surface of the first layer, the nanowells configured to selectively bind the particular types of complexes with the exposed surfaces of the first layer. One or more magnetic sensors are arranged from beneath the exposed surface of each of the nanowells, the magnetic sensors configured to respectively detect the presence of the target biomolecules through detection of the magnetic nanoparticles within the complexes.
G01N 27/74 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
B05D 7/00 - Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
B32B 9/04 - Layered products essentially comprising a particular substance not covered by groups comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance
B32B 15/04 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
B82Y 25/00 - Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
To provide a container storage device that reduces a decrease in processing capacity of an automatic analyzer to be connected and a delay in a measurement result of a measurement request sample and efficiently conveys the sample. A container storage device 1 includes a buffer 21 in which a rack 23 configured to accommodate a first container 22 and a second container 22 is placed, and a control unit 101. The control unit 101 includes a reception unit 102 configured to receive conveying commands for the first container 22 and the second container 22 from an analyzer 11, is configured to confirm whether a predetermined time elapses since the reception unit 102 receives the conveying command for the first container 22, and is configured to perform control such that when the conveying command for the second container 22 is received before the predetermined time elapses, the rack 23 on which the first container 22 and the second container 22 are placed is conveyed to the analyzer 11 at a timing at which the conveying command for the second container 22 is received, and when the conveying command for the second container 22 is not received even after the predetermined time elapses, the rack 23 on which the first container 22 is placed is conveyed to the analyzer 11.
A drug discovery ecosystem may receive one or more user inputs configuring an artificial intelligence (Al) agent for orchestrating a drug discovery workflow applying one or more drug discovery tools. The artificial intelligence (Al) agent may be created in accordance with the one or more user inputs. The artificial intelligence (Al) agent is served to one or more users as part a selection of artificial intelligence (Al) agents. One or more user inputs selecting the artificial intelligence (Al) agent may be received. The artificial intelligence (Al) agent may be executed to orchestrate the drug discovery workflow in response to the one or more user inputs selecting the artificial intelligence (Al) agent. Related systems, computer-implemented methods, and computer program products are provided.
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
laboratory instruments for the analysis of biological samples for use in research, science and industry; quantitative polymerase chain reaction (pcr) instruments for use in research, science and industry; downloadable computer software for use in medical decision support systems; downloadable laboratory workflow management system software; downloadable bioinformatics software; computer hardware and downloadable computer software for use with laboratory instruments, namely, for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management; integrated software packages for use in the automation of laboratories; downloadable software for healthcare information management and analysis for medical research and clinical research use Medical apparatus and instruments for medical and diagnostic purposes for the analysis of biological samples; medical apparatus, namely, clinical chemistry analyzers and immunochemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes; quantitative polymerase chain reaction (pcr) instruments for clinical medical diagnostic use
Provided is an automatic analysis device that is capable of suppressing intake, by a liquid intake nozzle, of bubbles that remain in a container after having been discharged thereinto from a liquid discharge nozzle. An automatic analysis device 100 comprises: an analysis part 45 that analyzes a specimen; a cup 39 that accommodates a liquid necessary for detection of the specimen; a first nozzle 38 that discharges the liquid into the cup 39; and a second nozzle 42 that intakes the liquid from the cup 39 and that feeds the liquid to the analysis part 45. The cup 39 is provided with a first region 54 into which the liquid is discharged from the first nozzle 38, a second region 55 from which the second nozzle 42 intakes the liquid, and a bubble blocking part 30a, 30b which is between the first region 54 and the second region 55, through which the liquid passes, and which blocks bubbles created by discharge of the liquid.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Scientific apparatus and instruments; Laboratory instruments [other than for medical use]; Instruments for diagnosis [for scientific use]; Quantitative Polymerase Chain Reaction [PCR] instruments for scientific use; Real-time Polymerase Chain Reaction [PCR] instruments for scientific use; Diagnostic apparatus for research laboratory use; Research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; Laboratory instrument for the detection of pathogens and toxins in a biological sample for research use; Computer software for use in medical decision support systems; Workflow management system software; Bioinformatics software; Computer software relating to the medical field; Integrated software packages for use in the automation of laboratories; Downloadable computer software for remote monitoring and analysis; Downloadable software applications. Medical apparatus and instruments; Testing apparatus for medical purposes; Diagnostic apparatus for medical purposes; Devices for measuring blood sugar; Real-time Polymerase Chain Reaction [PCR] instruments for medical use; Diagnostic testing instruments for use in immunoassay procedure [medical]; Immunochemical medical diagnostic testing apparatus for detecting and measuring antibody levels; Apparatus for analysing substances [for medical use]; Diagnostic apparatus for medical purposes for use in medical laboratories.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical preparations for scientific purposes, other than for medical or veterinary use; biological preparations, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; diagnostic reagents for scientific or research use; reagents for use in scientific apparatus for chemical or biological analysis; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; antibody reagents for scientific purposes; immunoassay reagents, other than for medical use; nucleic acids for scientific purposes; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; enzymes for scientific purposes; chemical reagents for use in genetic research. Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use for medical purposes; diagnostic biomarker reagents for medical purposes; immunoassay reagents for medical use; nucleic acid sequences for medical and veterinary purposes
The present invention relates to antibodies or antigen binding fragments thereof binding to Hemoglobin A1c (HbA1c) and nucleic acids coding for at least a part of antibodies or antigen binding fragments thereof binding to Hemoglobin A1c (HbA1c) of the present invention. Furthermore, the present invention relates to the use of antibodies or antigen binding fragments thereof binding to Hemoglobin A1c (HbA1c), compositions or diagnostic compositions of the present invention for determining the amount or concentration of HbA1c in a sample and to methods of for determining the amount or concentration of HbA1c in a sample.
The present invention concerns the field of diagnostics. In particular, it relates to a method for analyzing a protein analyte in a heparin-treated sample comprising or suspected to comprise said protein analyte, said method comprising the step of contacting said heparin-treated sample with spermidine prior to analyzing the said protein analyte in the said sample. Moreover, contemplated are a method for assessing a cardiovascular disease or disorder, a neurological disease or disorder, a metabolic disease or disorder or cancer as well as kits and reagent compositions comprising spermidine to be used in the said methods.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical preparations for scientific purposes, other than for medical or veterinary use; biological preparations, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; diagnostic reagents for scientific or research use; reagents for use in scientific apparatus for chemical or biological analysis; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; antibody reagents for scientific purposes; immunoassay reagents, other than for medical use; nucleic acids for scientific purposes; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; enzymes for scientific purposes; chemical reagents for use in genetic research. Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes]; diagnostic biomarker reagents for medical purposes; immunoassay reagents for medical use; nucleic acid sequences for medical and veterinary purposes.
This automated analyzer comprises: a dispensing unit that dispenses a specimen and a reagent into a first container; an analysis unit that analyzes components of the specimen by using a liquid mixture composed of the specimen and the reagent; a nozzle that suctions the liquid mixture from the first container and sends the liquid mixture to the analysis unit; and a control unit that controls the dispensing unit, the analysis unit, and the nozzle. The automated analyzer has set therein: an analysis step in which at least a first process for dispensing the specimen and the reagent into the first container, a second process for sending the liquid mixture from the first container to the analysis unit, and a third process for analyzing the components of the specimen by using the liquid mixture in the analysis unit are performed in the stated order; and a cleaning step in which at least a fourth process for sending a cleaning liquid from a second container to the analysis unit via the nozzle is executed. The control unit schedules the cleaning step to be executed between a plurality of analysis steps executed sequentially in the analysis unit. Consequently, carry-over can be reduced even when a low sensitivity item and a high sensitivity item are measured continuously.
The present disclosure provides for devices, compositions, and methods for improving signal variability in electrochemical detection, such as electrochemical detection with a biochip, such as a biochip including a gold electrode.
A first aspect of the invention relates to an aqueous formulation of a protein-loaded magnetic particle, the formulation comprising: (i) at least one protein-loaded magnetic particle; (ii) at least one aqueous phase; wherein the at least one protein-loaded magnetic particle of (i) is at least partially suspended in the at least one aqueous phase of (ii), the formulation further comprising: (iii) at least one detergent in a concentration of in the range of from 0.01 to 0.04 % (w/v); (iv) at least one blocking reagent in a concentration ≤ 0.02 mg/ml; (v) at least one inorganic salt in a concentration ≤ 300 mM; and (vi) at least one buffering system; wherein the at least one protein-loaded magnetic particle of (i) is present in the aqueous formulation in a concentration of ≥ 10 mg/ml; and the aqueous formulation has a pH in the range of from 6 to 7. In a second aspect, the invention relates to the use of an aqueous formulation according to the first aspect of the invention for storage, transportation, homogenization, filling, decanting and/or diagnostic purpose. A third aspect of the invention is directed to an aqueous composition, preferably for containing a protein-loaded magnetic particle, the composition comprising water and in dissolved and/or suspended form (iii), (iv), (v) and (vi) as in the formulation of the first aspect of the invention, wherein the aqueous composition has a pH in the range of from 6 to 7. A fourth aspect of the invention relates to the use of the aqueous composition of the third aspect for suspending at least one protein-loaded magnetic particle.
The invention relates to a laboratory sample distribution device (1), comprising: a base (2) having a transport surface (3), at least one drive-controllable lane belt (4) defining a transport lane (5), the lane belt (4) being cleated for form-fit engagement with a respective sample container carrier (50) to be moved over the transport surface (3) along the transport lane (5), at least one drive-controllable cross-track belt (6) defining a transport cross-track (7), the cross-track belt (6) being cleated for form-fit engagement with a respective sample container carrier (50) to be moved over the transport surface (3) along the transport cross-track (7), the transport cross-track (7) meeting the transport lane (5) at an angle (α), an operation mode in which the lane belt (4) and the cross-track belt (6) are controlled for transferring a respective sample container carrier (50) between the transport lane (5) and the transport cross-track (7), and another operation mode in which the lane belt (4) and the cross-track belt (6) are controlled for moving a respective sample container carrier (50) along the transport lane (5) past the transport cross-track (7).
The invention is directed in a first aspect to an aqueous formulation of a protein-loaded magnetic particle, the formulation comprising (i) at least one protein-loaded magnetic particle present in an aqueous phase in a concentration of ≥ 10 mg/ml; and (ii) at least one non-chelating biocide, wherein the at least one non-chelating biocide is at least partially dissolved respectively in the aqueous phase of (i), and the aqueous formulation, especially the aqueous phase, has a pH value in the range of from 6 to 7. A second aspect of the invention is directed to the use of the aqueous formulation according to the first aspect of the invention for storage, transportation, homogenization, purification, filling, decanting and/or diagnostic purpose.
The present invention provides novel antibodies specifically binding to ERG and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
25.
SERUM TRANSCRIPTIONAL REGULATOR ERG AS BIOMARKER FOR ENDOMETRIOSIS
The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, to methods for classifying the stage of endometriosis in a subject, by determining the amount or concentration of ERG in a sample of the subject, and comparing the determined level to a reference value.
Total internal reflection fluorescence (TIRF) microscope (100) comprising: an excitation light source (101) and an excitation light path (108), the excitation light source (101) being configured to emit an excitation light (110) propagating along the excitation light path (108) towards a sample (106) with at least one fluorophore and to generate an evanescent wave that is configured to permeate the sample and that is configured to excite an emission of fluorescence emission light (107) by the sample (106); an optical microscope setup (300) configured to project an image of at least a portion of the sample (106) positioned in an object plane (OP) onto an image plane (IP) of the optical microscope setup (300); a sensor (304) configured to be positioned in the image plane (IP) and to record the fluorescence emission light (107) emitted by the sample (106); and a total internal reflection (TIR) prism (201; 501; 600; 700) configured to support the sample (106), the total internal reflection (TIR) prism (201; 501; 600; 700) comprising: a base surface (A) facing away from the sensor; a sample-supporting surface (B) opposite to the base surface (A) and facing the sensor; an excitation light incidence surface (C) oriented at an angle 0° < ∝ < 90° with respect to the sample-supporting surface (B) and the excitation light path (108) being configured such that at least a portion of the excitation light (110) hits the excitation light incidence surface (C) and propagates via the TIR prism (200; 500; 600; 700) to the sample-supporting surface (B); an excitation light exit surface (D) opposite the excitation light incidence surface (C); and at least one light trap element (202; 502; 602; 703) matching the refractive index of the TIR prism (200; 500; 600; 700) and being optically coupled to the excitation light exit surface (D) of the TIR prism (200; 500; 600; 700).
ROCHE DIAGNOSTICS INTERNATIONAL AG (ROTKREUZ) (Germany)
Inventor
Carrillo Roa, Tania
Gruenewald, Felix
Heinz, Kathrin
Von Holtey, Maria
Klammer, Martin
Plaszczyca, Anna Maria
Wolfertstetter, Franziska
Abstract
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with infection comprising the steps of determining the amount or concentration of a biomarker in a sample of the subject, said biomarker being PPBP, comparing the amount of the biomarker to a reference for said biomarker and assessing said subject based on the comparison. The invention also relates to the use of a biomarker being PPBP or a detection agent specifically binding to said biomarker for assessing a subject with infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with infection and a device and a kit for assessing a subject with infection.
The present invention relates to a method for assessing asymptomatic heart failure said method comprising cMyBP-C (Myosin binding protein C, cardiac type), and optionally the level of at least one further biomarker selected from the group consisting of MyL7 (Myosin light chain 7), at least one cardiac Troponin, Angiopoietin-2 (Ang-2), and at least one BNP -type peptide in a sample from the subject. The present invention further relates to computer-implemented methods, databases, devices, kits and uses related thereto.
The disclosure relates to ssDNA cleavage using restriction enzymes, as well as its use for sequence specific hydrolysis of oligonucleotides prior to LC-MS/MS analysis resulting in formation of shorter oligonucleotide sequences to enable high sequence coverage by MS/MS fragmentation.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
30.
SYNTHESIS OF STABLE ISOTOPE LABELED VERSIONS OF N-(4-HYDROXYPHENYL)ACETAMID
The present invention relates to methods to prepare an isotopically labelled N-(4- hydroxyphenyl)acetamid, methods to prepare isotopically labelled 4-aminophenol and isotopically labelled 4-((4-nitrophenyldiazenyl)phenol. The present invention further relates to uses of an isotopically labelled N-(4-hydroxyphenyl)acetamid as an internal standard to determine the presence, amount or concentration of N-(4- hydroxyphenyl)acetamid in a sample and to methods of determining the amount of N-(4-hydroxyphenyl)acetamid in a sample. The present invention also relates to diagnostic compositions comprising an isotopically labelled N-(4- hydroxyphenyl)acetamid and kits for determining the presence, amount or concentration of N-(4-hydroxyphenyl)acetamid in a sample.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
31.
DIAGNOSTIC METHOD OF DETERMINING THE PRESENCE OF A LABEL-FREE ANTIBODY-ANTIGEN COMPLEX OF INTEREST IN A BIOLOGICAL SAMPLE
Diagnostic method (100) of determining the presence of a label-free antibody-antigen complex of interest in a biological sample: Providing (101) a trained model based on a training data set processed by multivariate statistics and a machine learning algorithm, wherein the training data set comprises: immunoassay training data of the labeled antibody-antigen complex obtained from at least one immunoassay technique; spectral training data comprising one or more training vibrational spectra of the labeled and/or label-free antibody-antigen complex obtained from at least one vibrational spectroscopy technique; Recording (102) at least one sample vibrational spectrum of a biological sample using the at least one vibrational spectroscopy technique; and Applying (103) the trained model onto the at least one sample vibrational spectrum and determine whether or not the label-free antibody-antigen complex is present in the biological sample.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
32.
METHOD FOR DERIVATIZING AND METHOD FOR DETERMINING AN ANALYTE OF INTEREST
The invention relates in a first aspect to a method for derivatizing an analyte of interest, wherein the method comprises the provision of (a) a liposome particle comprising a derivatization agent for an analyte intended to be analyzed via mass spectrometry, an encapsulating material surrounding the derivatization agent, and a first member of a binding pair bonded to at least a part of the encapsulating material and facing towards the outside of the particle; (b) a magnetic particle having on its surface a second member of the binding pair, and optionally a binding agent specific for the analyte of interest; (c) a liquid sample potentially containing an analyte of interest; and (d) optionally a further magnetic particle comprising a binding agent specific for the analyte of interest. The first aspect also relates to a method for determining an analyte of interest, the method further comprising subjecting the derivatized analyte of interest obtained to analysis. A second aspect of the invention is directed to a derivatized analyte of interest, obtained or obtainable from the method of the first aspect of the invention. In a third aspect, the invention is related to a liposome particle comprising a derivatization agent for an analyte intended to be analyzed via mass spectrometry, an encapsulating material surrounding the derivatization agent, and a first member of a binding pair bonded to at least a part of the encapsulating material, wherein the encapsulating material comprises one or more lipid(s) or to a liquid mixture comprising said liposome particle in suspended form. A fourth aspect of the invention is related to the use of the liposome particle or the liquid mixture of the third aspect of the invention for derivatization of an analyte of interest or in a method for determining an analyte of interest.
This gear pump performance prediction system for an automatic analysis device makes it possible to accurately predict the service life and replacement time of a gear pump of an automatic analysis device. The gear pump performance prediction system comprises: dispensing mechanisms 7, 8, 11, 12; a gear pump 41 that supplies washing water; a water supply pump 54; a first liquid delivery flow path 115 that delivers water from the water supply pump 54 to the gear pump 41; a second liquid delivery flow path 116 that delivers washing water from the water supply pump 54 to the dispensing mechanisms 7, 8, 11, 12; a pressure sensor 111 that measures the pressure values of the first liquid delivery flow path 115 and the second liquid delivery flow path 116; and a control unit 112 that adjusts the flow rate of the gear pump 41 by comparing an adjustment target pressure for the second liquid delivery flow path 116 and a measured pressure value 303. The state of the gear pump 41 is predicted by a gear pump performance evaluation unit 132 on the basis of a performance evaluation factor for the gear pump 41, and the state of the gear pump 41 predicted by the gear pump performance evaluation unit 132 is output to a data output unit 131 that outputs the predicted state of the gear pump 41.
Provided is a flow path abnormality detection system for detecting an abnormality on the basis of data obtained from an automatic analysis device, wherein the automatic analysis device includes: a sensor for applying a voltage to a reaction liquid, which is obtained by an antigen-antibody reaction between a specimen and a reagent, to cause an electrochemical reaction; a flow path for introducing, into the sensor, the reaction liquid and an auxiliary reagent for energization; and a photoelectric conversion sensor for measuring the emission intensity due to the electrochemical reaction. The flow path abnormality detection system comprises: a processor for calculating a feature amount from electrical signal data over time during a period in which the electrochemical reaction is being performed, and identifying an abnormality in the flow path from the feature amount; and a data output interface for outputting a signal pertaining to the result of the abnormality identified by the processor, wherein the processor obtains, from acquired electrical signal data, the feature amount on the basis of the emission intensity measured by the photoelectric conversion sensor. Thus, provided are a flow path abnormality detection system, an automatic analysis device, and a flow path abnormality detection method with which it is possible to automatically detect an abnormality in a flow path of the automatic analysis device.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
35.
AUTO-ANTIBODIES TO ANPEP FOR ASSESSING COLORECTAL CANCER (CRC) OR A PRECANCEROUS CONDITION THEREOF
The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising a) detecting the presence or absence of an antibody to ANPEP (Aminopeptidase N, anti-ANPEP antibody) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the presence or absence of an antibody to ANPEP determined in step a). The present invention further relates to computer-implemented methods, databases, devices, kits and uses related thereto.
The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level of SRY-box transcription factor 9 (SOX9) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of SOX9 determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
This automated analysis device comprises: a pump that feeds a mobile phase; a separating column through which the mobile phase fed by the pump and a specimen being analyzed are passed to separate components in the specimen; an acquiring unit that acquires pressure data when the pump feeds the mobile phase; a storage unit that stores a normal value of the pressure data; and a calculating unit that, each time a specimen is measured using the separating column, calculates first data indicating the degree of deviation of the pressure data from the normal value on the basis of a statistical method that takes into account the degree of similarity between the pressure data and the normal value, and calculates the remaining service life of the separating column on the basis of the first data. This makes it possible to provide an automated analysis device in which it is possible to predict more accurately the remaining service life of a separating column used in a liquid chromatograph.
The present invention relates to a mutated neuraminidase enzyme, or a functional fragment thereof with increased enzymatic activity at alkaline pH, compared to a non-mutated neuraminidase enzyme. The invention further provides nucleic acids encoding the mutant enzyme, a vector, a recombinant cell comprising the nucleic acid and a method for producing the enzyme. Also provided are a method for immunohistochemical (IHC) staining, the use of the mutated enzyme in immunohistochemical (IHC) staining, as well as a kit comprising the mutated enzyme.
The present invention relates to a mutated neuraminidase enzyme, or a functional fragment thereof with increased enzymatic activity at alkaline pH, compared to a non-mutated neuraminidase enzyme. The invention further provides nucleic acids encoding the mutant enzyme, a vector, a recombinant cell comprising the nucleic acid and a method for producing the enzyme. Also provided are a method for immunohistochemical (IHC) staining, the use of the mutated enzyme in immunohistochemical (IHC) staining, as well as a kit comprising the mutated enzyme.
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
40.
CLEC3B FOR ASSESSING COLORECTAL CANCER (CRC) OR A PRECANCEROUS CONDITION THEREOF
The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level CLEC3B (C-type lectin domain family 3 member B) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of CLEC3B determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes; Biological preparations for use in industry and science; Diagnostic reagents for scientific purposes; Diagnostic reagents for scientific or research use; Chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; Enzymes for scientific and research purposes; Chemical reagents for use in genetic research; Nucleic acids for scientific purposes
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes; Biological preparations for use in industry and science; Diagnostic reagents for scientific purposes; Diagnostic reagents for scientific or research use; Chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; Enzymes for scientific and research purposes; Chemical reagents for use in genetic research; Nucleic acids for scientific purposes
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than for medical or veterinary use; biological preparations, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; diagnostic reagents for scientific or research use; reagents for use in scientific apparatus for chemical or biological analysis; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; nucleic acids for scientific purposes; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; enzymes for scientific purposes; chemical reagents for use in genetic research.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than for medical or veterinary use; Biological preparations, other than for medical or veterinary purposes; Biochemical preparations for scientific purposes; Diagnostic reagents for scientific or research use; Reagents for use in scientific apparatus for chemical or biological analysis; Chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; Nucleic acids for scientific purposes; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Enzymes for scientific purposes; Chemical reagents for use in genetic research.
45.
METHOD OF AND SYSTEM FOR CHARACTERIZING AT LEAST ONE BIOMEDICAL POTENTIOMETRIC ELECTROCHEMICAL SENSOR
A method of characterizing at least one biomedical potentiometric electrochemical sensor (110) is proposed. The biomedical potentiometric electrochemical sensor (110) comprises at least one main electrode (112) with at least one ion-selective membrane, at least one reference electrode (114), and at least one counter electrode (116). The method comprises: (120) connecting the main electrode (112) with the reference electrode (114); (122) determining a potential between the main electrode (112) and the reference electrode (114) by a high-impedance potentiometric measurement; (124) connecting the one main electrode (112) with the counter electrode (116) and applying the determined potential between the main electrode (112) and the counter electrode (116); (126) recording electrochemical impedance data by performing an electrochemical impedance spectroscopy measurement (EIS), wherein the electrochemical impedance spectroscopy measurement comprising applying an alternating voltage; (128) de-connecting the main electrode (112) from the counter electrode (116) after applying the alternating voltage; and (130) characterizing the biomedical potentiometric electrochemical sensor (110) based on the recorded electrochemical impedance data.
In a detection process including an electrochemical reaction, the present invention stores, out of electric signal data acquired by a sensor, a parameter representing the relationship between the state of the sensor and the amount of change in the electric signal data due to change in the state of the sensor, calculates a state estimation index of the sensor using the electric signal data and the parameter, and calculates a statistical value of the state estimation index. In the detection process, the present invention calculates an evaluated sensor state estimation index of a sensor of interest using the parameter and evaluated sensor electric signal data output from the sensor of interest, compares the evaluated sensor state estimation index with the statistical value, evaluates a characteristic of the sensor of interest, and outputs the result of the characteristic evaluation. Thus, the present invention provides: a characteristic evaluation system with which it is possible to evaluate a characteristic of a sample test sensor of an automatic analysis device; an automatic analysis device; and a characteristic evaluation method.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
AUTOMATED METHOD AND ELECTRICAL CIRCUIT FOR ADJUSTING THE INTENSITY OF A LIGHT EMITTED BY A LIGHT-EMITTING DIODE TO A PREDETERMINED CONTROL VALUE AND IN VITRO DIAGNOSTIC TEST DEVICE COMPRISING SAID ELECTRICAL CIRCUIT
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Diagnostic preparations for research laboratory use;
diagnostic reagents for scientific or research use;
diagnostic reagents for in vitro use in biochemistry,
clinical chemistry and microbiology; calibration fluids for
medical apparatus; reagents in kit form for conducting
enzyme-linked immunosorbent assays (elisa) [other than for
medical or veterinary purposes]; chemicals for use in
performing nucleic acid polymerase chain reactions [other
than medical and veterinary]. Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes; nucleic
acid sequences for medical and veterinary purposes. Scientific research in the field of genetics and genetic
engineering; genetic testing for scientific research
purposes; scientific advisory services relating to chemical
reagents; laboratory testing; biochemical research and
analysis.
49.
METHODS AND COMPOSITIONS FOR STRAND ENRICHMENT AND TEMPLATE PREPARATION FOR SEQUENCING BY EXPANSION
The present invention relates to methods and compositions for preparing a sample enriched for single stranded nucleic acids. The single stranded nucleic acids find use as templates for synthesizing Xpandomer copies of the nucleic acids. The Xpandomer copies may be passed through a nanopore sensor to determine the nucleic acid sequence of the nucleic acids. The methods include asymmetric PCR, amplicon immobilization melt, exonuclease-mediated partial or complete digestion of one or both strand of an amplicon and linear amplification.
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
The present invention relates to a method for extracting a macrocyclic analyte from a sample, said method comprising (a) producing a lysis admixture comprising said sample, a first organic solvent at a concentration of from 2.5% (v/v) to 18% (v/v), and an aqueous component at a concentration of at least 60% (v/v), and contacting said lysis admixture with a solid-phase extraction agent; (b) obtaining solid-phase extraction agent bound sample constituents; and (c) thereby extracting said macrocyclic analyte. The present invention also relates to systems, kits, extracts, and determining methods related thereto.
The present disclosure relates, in general, to novel and easily accessible fluorescent compounds with improved fluorescence properties for expanding the multiplexing capabilities of fluorescence-based nucleic acid detection technologies, as well as to novel methods of producing the same. Moreover, conjugates, PCR probes and FRET pairs comprising these fluorescent compounds as well as methods for amplification and detection of a target nucleic acid utilizing these fluorescent compounds and methods of labeling are also provided.
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
In a first aspect, the present invention is directed to a magnetic particle having a saturation magnetization ≥ 15 Am2/kg and having at least one azide group –N=N'-N- bonded to a polymer matrix of the magnetic particle. A second aspect of the invention relates to a process for preparing a magnetic particle, which comprises at least one magnetic core (M), a polymer matrix (P) comprising a crosslinked polymer at least partially surrounding the magnetic core (M), the polymer matrix (P) comprising on its surface at least a functional group reactive towards amine groups and/or hydroxyl groups. In a third aspect, the invention is directed to the magnetic particle obtained or obtainable from the process of the second aspect. A fourth aspect is related to a process for preparing a magnetic particle having a saturation magnetization ≥ 15 Am2/kg of the first aspect, and a fifth aspect relates to the magnetic particle obtained or obtainable from the process of the fourth aspect. A sixth aspect is directed to the use of the magnetic particle having a saturation magnetization ≥ 15 Am2/kg of the first aspect or of the fourth aspect for qualitative and/or quantitative determination of at least one analyte in a fluid or in a gas, and a seventh aspect relates to a method for determining at least one analyte in a fluid using said magnetic particle having a saturation magnetization ≥ 15 Am2/kg.
A computer-implemented method for determining if adding a batch of data to an extant dataset, thereby creating an updated extant dataset, would result in additional data being shareable under an anonymization scheme, whereby the data in the batch of data and the extant dataset contain or represent personally identifiable information linked to one or more values The method comprises: receiving the batch of data or a representation thereof; determining whether at least a subset of the updated extant dataset including at least a portion of the received batch of data would be compatible with the anonymization scheme; and responsive to determining that it would be, transmitting to a recipient a share enable message so as to cause the creation of an anonymization of the at least a subset of the updated extant dataset in accordance with the anonymization scheme and the publication of this anonymized data.
The present invention generally relates to the field of metabolite analysis as it applies to compounds, formulations and methods which can be used to detect metabolites such as formaldehyde and methanol. More particularly, the present invention pertains to β-keto amide compounds which are particularly useful as superior and sufficiently chemoselective detection reagent in the detection of metabolites, notable formaldehyde and related compounds, such as methanol. The present invention also pertains to methods for detecting formaldehyde or methanol, as well as to formulations and kits comprising the β-keto amide compounds, and to the use thereof in the detecting formaldehyde or methanol.
C07C 235/80 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
55.
ECO-FRIENDLY ANALYTIC FLUID DEVICE AND METHOD OF PRODUCING AN IN VITRO DIAGNOSTIC FLUID DEVICE
Analytic fluid device (1) comprising: a substrate (2); a channel negative layer (3) printed onto the substrate (2) and forming at least partially a capillary channel (4) that is configured to guide a fluid (9) along a path (5) that is at least partially defined by the capillary channel (4); and at least one porous fluid reservoir (6) coupled to the capillary channel (4) and configured to receive at least a portion of the fluid (9) after being guided along the path (5) and/or provide at least a portion of the fluid (9) before being guided along the path (5).
The present invention generally relates to the field of metabolite analysis as it applies to compounds, formulations and methods which can be used to detect metabolites such as formaldehyde and methanol. More particularly, the present invention pertains to β-keto amide compounds which are particularly useful as superior and sufficiently chemoselective detection reagent in the detection of metabolites, notable formaldehyde and related compounds, such as methanol. The present invention also pertains to methods for detecting formaldehyde or methanol, as well as to formulations and kits comprising the β-keto amide compounds, and to the use thereof in the detecting formaldehyde or methanol.
C07D 211/84 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C07C 235/80 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic preparations for research laboratory use;
diagnostic reagents for scientific or research use;
diagnostic reagents for in vitro use in biochemistry,
clinical chemistry and microbiology; calibration fluids for
medical apparatus; reagents in kit form for conducting
enzyme-linked immunosorbent assays (elisa) [other than for
medical or veterinary purposes]; chemicals for use in
performing nucleic acid polymerase chain reactions [other
than medical and veterinary]. Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes; nucleic
acid sequences for medical and veterinary purposes.
58.
HANDHELD DEVICE FOR THE DETECTION OF ELECTROSTATIC DISCHARGE
The present invention is directed to a handheld device for the detection of electrostatic discharge, comprising an evaluation unit, and a cable antenna, wherein the cable antenna is formed in a coil-like manner with a number n of windings, with n≥2, each winding being wound around a winding axis, a diameter of each winding is less than 30 cm, and the windings of the cable antenna are spaced apart from each other, preferably by means of at least one spacer.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Laboratory instruments, namely, clinical chemistry analyzers and immunochemistry analyzers for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for scientific or medical research purposes; computer hardware and downloadable software for use with laboratory instruments, namely, for use in data analysis and database management Medical apparatus, namely, clinical chemistry analyzers and immunochemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
60.
METHODS FOR CORRECTING A DC CURRENT, RECORDED BY AN AMPEROMETRIC SENSOR IN CONTACT WITH A MEDICAL FLUID, FOR A TIME-DEPENDENT HCT-INDUCED CURRENT DRIFT
The present invention relates to a hepatitis delta virus (HDV) polypeptide comprising an antigenic domain comprising an amino acid sequence of SEQ ID NO:1 or an amino acid sequence at least 60% identical thereto, wherein said polypeptide (i) is devoid of a coiled-coil domain consisting of the amino acid sequence of SEQ ID NO:2 or an amino acid sequence at least 60% identical thereto; or (ii) further comprises said coiled-coil domain, wherein said coiled-coil domain comprises at least one of the following mutations: (I) the amino acid at position 20 is not tryptophan, and (II) the amino acid at position 50 is not tryptophan. Moreover, the present invention relates to proteins, kits, polynucleotides, host cells, methods, and devices related thereto.
The present invention provides for monoclonal antibodies binding to sulfated and non-sulfated amidated gastrin 17. Further, the present invention provides for kits and compositions comprising such antibodies and diagnostic uses and methods employing such antibodies, compositions, and/or kits. Furthermore, herein provided are, inter alia, nucleic acids encoding such antibodies, host cells comprising the same, as well as means and methods for the production of such antibodies.
The present invention relates in a first aspect to an electrode for an analyte sensor, comprising a layer, which comprises silver chloride (AgCl) and a thermoplastic polyurethane, wherein the thermoplastic polyurethane is obtained or obtainable from an aliphatic polyisocyanate and a polyether polyol. A second aspect of the invention relates to an analyte sensor comprising an electrode of the first aspect of the invention. In a third aspect, the invention is directed to a method for manufacturing an electrode of an analyte sensor. A fourth aspect of the invention is directed to an electrode of an analyte sensor, obtained or obtainable from the method of the second aspect of the invention. In a fifth aspect, the invention is related to a method for manufacturing an analyte sensor as of the second aspect. A sixth aspect of the invention is directed to an analyte sensor, obtained or obtainable from the method of the fifth aspect of the invention. A seventh aspect of the invention is directed to a use of an analyte sensor of the sixth aspect for detecting at least one analyte.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic reagents for in vitro use in biochemistry,
clinical chemistry and microbiology; biological
preparations, other than for medical or veterinary purposes;
biochemical preparations for scientific purposes; diagnostic
reagents for scientific or research use; chemical substances
for analyses in laboratories, other than for medical or
veterinary purposes; chemical preparations for scientific
purposes, other than for medical or veterinary use. Chemical preparations for medical purposes; biochemical
preparations for medical use; in vitro diagnostic
preparations for medical use; diagnostic reagents for
medical use; reagents for in-vitro laboratory use [for
medical purposes]; biological preparations for medical
purposes.
65.
IN-VITRO DIAGNOSTICS SENSING SYSTEM AND IN-VITRO DIAGNOSTICS SENSING METHOD OF DETERMINING A PRESENCE OF A FLUID SUBSTANCE BASED ON RADIO-FREQUENCY TECHNOLOGY
In-vitro diagnostics (IVD) sensing system (10) for a determination of a presence of a fluid substance (1) based on radio-frequency (RF) technology, the IVD sensing system comprising: one or more antennas (2), wherein at least one first antenna (2a) of the one or more antennas (2) is configured to emit an RF signal (3a) and wherein the at least one first antenna (2a) and/or an at least one second antenna (2b) of the one or more antennas (2) is/are configured to receive the RF signal (3b) emitted by the at least one first antenna (2a); a sample space (4) being positioned with respect to the one or more antennas (2) such that the RF signal (3a) can pass at least a portion of the sample space (4) after being emitted and before being received and the sample space being configured to receive a sample support (5) for receiving the fluid substance (1); and a transformer (6) being configured to transform the received RF signal (3b) into a readable signal (7) that is sensitive to indicate the presence of the fluid substance (1) in the sample support (5) having a substance volume (V) in a range between 500µL and 0.1µL, specifically in a range between 20µL and 0.5µL.
G01N 22/00 - Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Diagnostic preparations for research laboratory use; diagnostic reagents for scientific or research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; calibration fluids for medical apparatus; reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) [other than for medical or veterinary purposes]; chemicals for use in performing nucleic acid polymerase chain reactions [other than medical and veterinary].
(2) Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes]; diagnostic biomarker reagents for medical purposes; nucleic acid sequences for medical and veterinary purposes. (1) Scientific research in the field of genetics and genetic engineering; genetic testing for scientific research purposes; scientific advisory services relating to chemical reagents; laboratory testing; biochemical research and analysis.
A system for managing heart disease, the system including a patient management platform for managing heart disease in patients, the patient management platform connected with one or more mobile and remote patient monitoring device(s) configured to remotely obtain patient physiological attributes outside of a clinic or hospital setting. The patient management platform is configured to receive patient data through electronic patient data systems (e g., an EMR) and compare the physiological attributes and patient data with at least one heart disease treatment protocol. Based on the analyzing, the platform determines one or more recommended action(s) to be taken according to at least one heart disease treatment protocol and generates a notification of the recommended action(s).
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Diagnostic preparations for research laboratory use; diagnostic reagents for scientific or research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; calibration fluids for medical apparatus; reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) [other than for medical or veterinary purposes]; chemicals for use in performing nucleic acid polymerase chain reactions [other than medical and veterinary].
(2) Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes]; diagnostic biomarker reagents for medical purposes; nucleic acid sequences for medical and veterinary purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
Goods & Services
Chemical, biological and biochemical preparations for scientific and research purposes; in vitro diagnostic reagents for use in industry and science; chemical preparations for use in chromatography; separation materials for use in liquid chromatography columns, namely, chromatography separation media for separation of a mixture into components; chemical reagents for use with spectrometers for analyzing biological samples in the clinical diagnostic field for research purposes Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; in vitro diagnostic reagents for the analysis of biological samples for medical purposes; in vitro diagnostic agents, namely, reagents and control solutions for analysis of biological samples for medical diagnostic purposes Laboratory instruments for laboratory use for use in preparation of biological samples, chromatography and analysis of biological samples for medical research purposes; spectrometers for laboratory use; chromatography columns for laboratory use with laboratory instruments for use in preparation of biological samples, chromatography and analysis of biological samples; downloadable computer software for laboratory use in the field of diagnostics, namely, software for storage, retrieval, and processing of mass spectrometry data; downloadable computer software for laboratory use featuring algorithms for laboratory test data analysis; downloadable computer software for laboratory use having processing algorithm used to identify, filter, analyze, visualize and manage data from biological information
70.
AN IN VIVO ANALYTE SENSOR AND A METHOD OF MANUFACTURING AN IN VIVO ANALYTE SENSOR
The present disclosure refers to an in vivo analyte sensor, comprising: a substrate (20); a conductive layer (21) disposed over at least a portion of the substrate (20); a sensing layer (24) disposed formed on the conductive layer (21), wherein the sensin\g layer (24) forms a sensing area configured to generate one or more signals identifying a monitored analyte level after insertion of the analyte sensor and when maintained in fluid contact with interstitial fluid; and a membrane layer (25) formed at least on the sensing layer (24). The sensing layer (24) is formed with an area sensitivity of 0,2 to 1,5 nA/(mqx/dL) mm2 within the sensing area. Further, a method of manufacturing an in vivo analyte sensor is provided.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
71.
FILLING LANCE DEVICE, CONTAINER SYSTEM AND METHODS FOR CONTAMINATION-FREE FILLING OF A CONTAINER WITH A SUBSTANCE AND CONCEPTS OF HANDLING AND DRYING, SPECIFICALLY LYOPHILIZATION OF THE SUBSTANCE
A filling lance device (40) configured for contamination-free filling of a container (20) with a substance (1), the filling lance device (40) comprising: a tubular filling lance (41) and a lance housing (46) enclosing at least partially the tubular filling lance (41), wherein the tubular filling lance (41) and the lance housing (46) are movably arranged relative to each other between at least one filling configuration (A) and at least one de-contamination configuration (B, C, D), wherein the lance housing (46) comprises a channel system (48) being fluidically connectable to an external suction pump (7) and wherein the at least one de-contamination configuration (B, C, D) corresponds to a configuration in which the channel system (48) is in fluidic connection with the tubular filling lance (41).
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 39/04 - Nozzles, funnels or guides for introducing articles or materials into containers or wrappers having air-escape, or air-withdrawal, passages
B65B 39/12 - Nozzles, funnels or guides for introducing articles or materials into containers or wrappers movable towards, or away from, container or wrapper during filling or depositing
F26B 5/04 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
F26B 5/12 - Drying solid materials or objects by processes not involving the application of heat by suction
72.
AUTOMATIC ANALYSIS DEVICE, ABNORMALITY DETECTION SYSTEM, AND ABNORMALITY DETECTION METHOD
An automatic analysis device 1 comprises: a flow path 41; a first electrode 42, a second electrode 43, and a reference electrode 44 which are electrodes 48 for applying a voltage to the flow path 41; a determination unit which determines the presence/absence of an abnormality in the flow path 41 and/or the electrodes 48; and a storage unit which stores a feature amount related to a first waveform indicating the waveform of a current flowing through one of the electrodes 48 in a prescribed effective time zone Z after the start of voltage application in the case where the flow path 41 and the electrodes 48 are normal and the voltage between the first electrode 42 and the reference electrode 44 is controlled to be a prescribed voltage value. The determination unit determines the presence/absence of an abnormality in the flow path 41 and/or the electrodes 48 by comparing the feature amount related to the first waveform and a feature amount related to a second waveform indicating the waveform of a current flowing through one of the electrodes 48 in the prescribed effective time zone Z after a prescribed period of time has passed since the feature amount related to the first waveform was stored in the storage unit. As a result, the presence/absence of an abnormality in components constituting a reaction unit can be detected.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 21/69 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence specially adapted for fluids
G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
73.
METHOD AND SYSTEM FOR IMPROVING BIOMARKER BASED DISEASE ASSESSMENTS
The present invention relates to the field of diagnostics. In particular, it relates to a computer-implemented method for assessing a medical condition in a subject comprising the steps of determining the amount of at least one biomarker of interest for said medical condition in a sample of the subject, comparing the determined amount of the at least one biomarker to a reference, and assessing the medical condition in the subject based on the comparison and improving the reliability of the said assessment by integrating at least one clinical parameter value of the medical condition obtained from a dataset of continuously determined clinical parameter values comprising the said at least one clinical parameter value into the biomarker-based assessment, wherein the sample and the at least one clinical parameter value have been obtained from the subject within a short time window, wherein said at least one biomarker is determined continuously by using a point-of-care analytical device and/or wherein the dataset comprising the at least one clinical parameter is determined by a wearable sensing device. Moreover, the invention provides a system and a device for assessing a medical condition in a subject as well as the use of the amount of at least one biomarker of interest for said medical condition in a sample of the subject or a detection agent therefor for assessing a medical condition in said subject.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
74.
PROTECTION OF SH-GROUP CONTAINING POLYPEPTIDES AGAINST INACTIVATION BY ISOTHIAZOLINONE TYPE COMPOUNDS
The present invention relates to a method for protecting and/or stabilizing free SH-group containing polypeptide against the inactivation thereof by an isothiazolinone type compound, comprising the step of covalently coupling at last one albumin to at least one free SH-group of the free SH-group containing polypeptide. Furthermore, the present invention relates to the stabilized free SH-group containing polypeptide, for example a biosensor, such as an enzyme used for indicating or detecting a biological state or medical parameter. The present invention also provides a method for producing a pharmaceutical composition comprising the stabilized free SH-group containing polypeptide, and a kit for use with the above-mentioned method.
A test kit (110), a test strip (112) and a method for determining analytes in a sample of a bodily fluid (111) are disclosed. The test kit (110) comprises: i) at least one test strip (112) comprising at least one membrane (114), wherein the membrane (114) comprises at least one first test field (116), the first test field (116) comprising at least one first capture component (118), wherein the membrane (114) further comprises at least one second test field (120), the second test field (120) comprising at least one second capture component (122), wherein the second capture component (122) is different from the first capture component (118); and ii) at least one first analyte detection system (124) for contacting with the sample of the bodily fluid (111), wherein the first analyte detection system (124) comprises at least one optode compound configured for receiving a first analyte suspected to be present in the sample of the bodily fluid (111), wherein the first analyte detection system (124) further comprises at least one first capture reagent; wherein the first capture component (118) is configured for capturing the first capture reagent of the first analyte detection system (124), wherein the second capture component (122) is configured for capturing at least one second capture reagent (136) from at least one second analyte detection system (126), the second capture reagent (136) being different from the first capture reagent.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
Goods & Services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes. Bio-sensors; biochip sensors; barcode scanners; bar code
printers; portable scanners; radio-frequency identification
(RFID) tags; application software for cloud computing
services; bags adapted for laptops; cases for tablet
computers; cases for data storage devices; computer software
for use in medical decision support systems; workflow
management system software; software as a medical device
[SaMD], downloadable; application software for mobile
devices, all the aforesaid goods related to the field of in
vitro diagnostics.
77.
A METHOD FOR DATA CLEANSING, A METHOD FOR PRE-PROCESSING HEALTHCARE PATIENT DATA PRIOR TO A DATA CLEANSING, AND A METHOD FOR POST-PROCESSING HEALTHCARE PATIENT DATA AFTER DATA CLEANSING
The present invention relates to a computer implemented method for data cleansing. In the method, a data pre-processing module of a first computing instance (3) obtains an at least two-dimensional un-shuffled data structure (10). The data structure (10) comprises healthcare patient data. The data structure (10) comprises data on a plurality of patient records. Each patient record comprises one or more fields wherein each field has a field type and wherein the patient records have a pre-shuffled order. The data pre-processing module of the first computing device shuffles fields of a first field type by moving fields having the first field types from one patient record to another patient record. Fields with the first field type have a post-shuffled order after the shuffling thereby creating a shuffled data structure(lO). A communications module transmits (5) the shuffled data structure (10) comprising the healthcare patient data over a communications network (7) from the first computing instance to a second computing instance.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; biological preparations, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; diagnostic reagents for scientific or research use; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use.
(2) Chemical preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes]; biological preparations for medical purposes.
A packaging element (110) for packaging medical consumables (112) is disclosed. The packaging element (110) comprises: a. at least one carrier sheet component (114) having formed therein at least one cavity (116) and having at least one rim (118) at least partially surrounding the cavity (116); b. at least one barrier (120); and c. at least one sealing sheet material (122) configured for being coupled at least partially to the rim (118) of the at least one carrier sheet component (114) and for sealing the at least one cavity (116), - wherein the at least one cavity (116) comprises at least one consumable compartment (124) for receiving the medical consumable (112) and at least one desiccant compart- ment (126) for receiving at least one desiccant (128), and - wherein the consumable compartment (124) and the desiccant compartment (126) are separated via the at least one barrier (120), the barrier (120) preventing desiccant (128) from entering the consumable compartment (124) and the barrier (120) allowing for water vapor moving from the consumable compartment (124) to the desiccant compartment (126). Further disclosed are a medical consumable kit (140), a method of manufacturing the medical consumable kit (140) and a use of the packaging element (110).
A61B 5/157 - Devices for taking samples of blood characterised by integrated means for measuring characteristics of blood
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
B65D 81/26 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, fluids, e.g. exuded by contentsApplications of corrosion inhibitors or desiccators
G01N 33/487 - Physical analysis of biological material of liquid biological material
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
Goods & Services
(1) Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes]; diagnostic biomarker reagents for medical purposes.
(2) Bio-sensors; biochip sensors; barcode scanners; bar code printers; portable scanners; radio-frequency identification (RFID) tags; application software for cloud computing services; bags adapted for laptops; cases for tablet computers; cases for data storage devices; computer software for use in medical decision support systems; workflow management system software; software as a medical device [SaMD], downloadable; application software for mobile devices, all the aforesaid goods related to the field of in vitro diagnostics.
The present invention relates to nucleic acids coding for a protein said protein comprising a glial fibrillary acidic protein (GFAP) and a eukaryotic secretion tag, proteins comprising a GFAP and a eukaryotic secretion tag, expression constructs comprising a nucleic acid coding for a protein which comprises a GFAP and a eukaryotic secretion tag, vectors comprising the nucleic acids or expression constructs disclosed herein and eukaryotic cells comprising a nucleic acid, expression construct or vector disclosed herein. The present invention furthermore relates to methods for the production of the herein disclosed proteins. The present invention also relates to compositions comprising the herein disclosed proteins and kits comprising the herein disclosed proteins and/or compositions. Furthermore, the present invention relates to the use of the herein disclosed proteins, compositions and/or kits for calibrating a measurement system for the in vitro quantification of GFAP or a variant thereof in a sample.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/62 - DNA sequences coding for fusion proteins
82.
EXPRESSION OF TRUNCATED GLIAL FIBRILLARY ACIDIC PROTEINS
The present invention relates to nucleic acids coding for a protein said protein comprising a truncated glial fibrillary acidic protein (GFAP), proteins comprising a truncated GFAP, expression constructs comprising a nucleic acid coding for a protein which comprises a truncated GFAP, vectors comprising the nucleic acids or expression constructs disclosed herein and eukaryotic cells comprising a nucleic acid, proteins, expression construct or vector disclosed herein. The present invention furthermore relates to compositions comprising the herein disclosed proteins and kits comprising the herein disclosed proteins and/or compositions. Furthermore, the present invention relates to the use of the herein disclosed proteins, compositions and/or kits for calibrating a measurement system for the in vitro quantification of GFAP or a variant thereof in a sample.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/62 - DNA sequences coding for fusion proteins
83.
SYSTEMS AND METHODS FOR DIGITAL CELL CULTURE ANALYSIS OF PATHOGEN AND HOST INTERACTIONS
e.g.e.g. a bacteriophage) in a sample, to determine a host range of a bacteriophage of interest, and to determine a phagogram of a bacterium of interest.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
84.
METHOD FOR PRODUCING RECOMBINANT VIRUSES OR VIRUS-LIKE PARTICLES (VLPs) IN MAMMALIAN CELL LINES
The present invention relates to a method for producing higher titers and/or a higher quality of recombinant viruses and/or less or reduced impurities in virus like particle (VLP) production in respective production processes in mammalian cell lines, the method comprising the step of supplementing a suitable mammalian cell line culture media with at least one intermediate substrate of the tricarboxylic acid (TCA) cycle and optionally supplementing the suitable mammalian cell line culture media with further additives and/or further adjusting the conditions of the mammalian cell line culture media. Furthermore, the present invention relates to the balanced suitable mammalian cell line culture media and the use of this balanced suitable mammalian cell line culture media for producing higher titers and/or a higher quality of recombinant viruses and/or less or reduced impurities in virus like particle (VLP) production in respective production processes for producing higher titers and/or quality of recombinant viruses.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic preparations for research laboratory use; Diagnostic reagents for scientific or research use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Calibration fluids for medical apparatus; Reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) [other than for medical or veterinary purposes]; Chemicals for use in performing nucleic acid polymerase chain reactions [other than medical and veterinary]. Chemical preparations for medical purposes; Biological preparations for medical purposes; Biochemical preparations for medical use; In vitro diagnostic preparations for medical use; Diagnostic reagents for medical use; Reagents for in-vitro laboratory use [for medical purposes]; Diagnostic biomarker reagents for medical purposes; Nucleic acid sequences for medical and veterinary purposes.
The disclosure relates to methods for amplifying a target nucleic acid. The methods include performing an amplifying step comprising contacting the nucleic acid with a polymerase, dNTPs, one or more set of primers specific for the nucleic acid, and an amplification enhancer that is methyl paraben or a derivative thereof. Also described are kits and reaction mixtures for the amplification of a target nucleic acid in the presence of the amplification enhancer, as well as methods for enhancing nucleic acid amplification.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Diagnostic preparations for research laboratory use; Diagnostic reagents for scientific or research use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Calibration fluids for medical apparatus; Reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) [other than for medical or veterinary purposes]; Chemicals for use in performing nucleic acid polymerase chain reactions [other than medical and veterinary]. Chemical preparations for medical purposes; Biological preparations for medical purposes; Biochemical preparations for medical use; In vitro diagnostic preparations for medical use; Diagnostic reagents for medical use; Reagents for in-vitro laboratory use [for medical purposes]; Diagnostic biomarker reagents for medical purposes; Nucleic acid sequences for medical and veterinary purposes. Scientific research in the field of genetics and genetic engineering; Advisory services relating to chemical reagents; Laboratory testing; Biological research and analysis.
88.
AUTONOMOUS MOBILE ROBOT MODULE AND AUTOMATED MODULAR LAB ASSISTANT SYSTEM COMPRISING THE AUTONOMOUS MOBILE ROBOT MODULE FOR PERFORMING MULTIPLE LABORATORY OPERATIONS
An autonomous mobile robot module (30) for performing multiple laboratory operations, wherein the robot module (30) comprises: a safety sensor for detecting a human; a robot module controller (30.14) configured to control the multiple laboratory operations and to stop at least one of multiple laboratory operations when the human is detected; a motor for driving a movement of the autonomous mobile robot module (30) controlled by the robot module controller (30.14); a robot platform for receiving objects; a robot arm configured for performing multiple laboratory operations controlled by the robot module controller (30.14); one or more tools being connectable to the robot arm, wherein the one or more tools comprises at least: a capper and/or decapper function for capping and/or decapping of containers; a pipetting function for pipetting liquids among the containers.
The present invention relates to methods for assessing heart muscle tissue damage. The methods are based on the determination of the biomarker MyL7 in a sample from a subject. Moreover, the present invention relates to the use of the biomarker MyL7 (Myosin regulatory light chain 2, atrial isoform) or of at least one detection agent which specifically binds to said biomarker in at least one sample from a subject for assessing heart muscle tissue damage. The present invention further relates to a kit for assessing heart muscle tissue damage.
Ttotaltotal total , to process the biological sample by the respective laboratory, and performing a routing action related to the biological sample on the basis of the respective total times Estimating the total time is performed using a model which includes one or more complexity factors indicating a complexity of one or more analytical tests to be performed by the respective laboratory, the complexity factors being derived from historical testing data.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
91.
HIGHLY SENSITIVE AND SELECTIVE MASS SPECTROMETRIC METHOD AND MASS SPECTROMETER SYSTEM FOR DETECTING AN ANALYTE IN A BIOLOGICAL SAMPLE
Mass spectrometric method (100) for detecting an analyte in a biological sample solution comprising the steps: providing (101) a constant stream of ionized sample molecules comprising the analyte from the biological sample solution and an analyte-specific internal standard including electrospray ionization (ESI), and/or nano-electrospray ionization (nano-ESI); performing (102a) a spatial accumulation of the analyte and the analyte-specific internal standard and performing (102b) at least partially a first separation of the analyte and the analyte-specific internal standard from other components of the ionized sample molecules based on the size and/or shape of the ionized molecules; performing (103) at least partially a second separation of the analyte and the analyte-specific internal standard from remained other components of the ionized sample molecules based on the mass to charge ratio of the ionized molecules; fragmenting (104) the ionized analyte into ionized analyte fragments and the analyte-specific internal standard into ionized analyte-specific internal standard fragments by collision with particles of a gas phase; providing (105) a stream comprising the ionized analyte fragments and the ionized analyte-specific internal standard fragments on a detection mass spectrometer; and recording (106) with the detection mass spectrometer at least two pre-summed mass-resolved spectra and summing (107) the at least two pre-summed mass-resolved spectra to obtain a final mass-resolved spectrum.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic preparations for
research laboratory use; diagnostic reagents for scientific
or research use; chemical reagents for use in genetic
research; chemical preparations for use in DNA analysis
[other than medical]; biomolecule labeling kits comprising
reagents for use in scientific research; biochemicals,
namely, monoclonal antibodies for in vitro scientific or
research use; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology;
calibration fluids for medical apparatus; reagents in kit
form for conducting enzyme-linked immunosorbent assays
(ELISA) [other than for medical or veterinary purposes]. In vitro diagnostic preparations for medical use; diagnostic
reagents for medical use; reagents for use in medical
genetic testing; reagents for in-vitro laboratory use [for
medical purposes]; chemical preparations for use in DNA
analysis [medical]; preparations for detecting genetic
predispositions for medical purposes; nucleic acid sequences
for medical and veterinary purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; instruments for diagnosis [for
scientific use]; quantitative polymerase chain reaction
[PCR] instruments for scientific use; real-time polymerase
chain reaction [PCR] instruments for scientific use;
laboratory devices for detecting genetic sequences;
diagnostic apparatus for research laboratory use; DNA
microarray; devices for analyzing genome information;
devices for analyzing protein sequence used as laboratory
apparatus; research laboratory analyzers for measuring,
testing and analyzing blood and other bodily fluids; nucleic
acid sequencers for scientific purposes; laboratory devices
for detecting genetic sequences; gene amplifiers; computer
software for use in medical decision support systems;
workflow management system software; bioinformatics
software. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes; real-time polymerase chain reaction
[PCR] instruments for medical use; diagnostic testing
instruments for use in immunoassay procedure [medical];
immunochemical medical diagnostic testing apparatus for
detecting and measuring antibody levels; apparatus for DNA
and RNA testing for medical purposes; apparatus for
analysing substances [for medical use]; diagnostic apparatus
for medical purposes used in medical laboratories; genetic
testing apparatus for medical purposes. Research in the field of DNA mutation; DNA screening for
scientific research purposes; laboratory research in the
field of gene expression; consultancy relating to laboratory
testing; medical research; research and development in the
field of diagnostic preparations; providing temporary use of
on-line non-downloadable operating software for accessing
and using a cloud computing network; information on the
subject of scientific research in the field of biochemistry
and biotechnology; software as a service [SaaS].
A sampling device (110) for sampling bodily fluid is proposed, comprising a stationary component (118) and a movable component (120) being movably mounted to the stationary component (118). The movable component (120) is movable from at least one distal position to at least one proximal position and back. The movable component (120) comprises at least one penetration element (132) for penetrating the skin of a user, which, in the distal position of the movable component (120), is received within the stationary component (118) and which, in the proximal position of the movable component (120), protrudes from an application side (128) of the stationary component (118). The movable component (120) comprises a container receptacle (134) for receiving at least one sample container (114) having a septum (136). The sampling device (110) further comprises a sample collection channel (138) for transporting sample from the application side (128) into the container receptacle (134). The sampling device (110) further comprises a pressure chamber (140) having a volume being dependent on the position of the movable component (120), wherein the volume when the movable component (120) is in the proximal position is smaller than the volume when the movable component (120) is in the distal position. The sampling device (110) further comprises a pressure adjustment channel (154) for transferring underpressure from the pressure chamber (140) into the sample container (114) through the septum (136) when the movable component (120) is retracted from the proximal position into the distal position. Further, a sampling kit (112) for sampling bodily fluid and a method for generating an underpressure in a sample container (114) having a septum (136) are proposed.
09 - Scientific and electric apparatus and instruments
Goods & Services
Bio-sensors; biochip sensors; barcode readers; bar code
printers; portable scanners; radio-frequency identification
(RFID) tags; interfaces for computers; electronic docking
stations; application software for cloud computing services;
cases for tablet computers; cases for data storage devices;
computer software relating to the medical field; computer
software for use in medical decision support systems;
workflow management system software; software as a medical
device [SaMD], downloadable; application software for mobile
devices.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical, biochemical and biological preparations for scientific and research purposes, namely, diagnostic and detection reagents for scientific and research purposes; chemical reagents for research or laboratory use, other than for medical or veterinary use; chemical reagents for the preparation and staining of tissue specimens for research purposes; chemical reagents for non-medical purposes, namely, for use in histological and cytological tissue processing Chemical, biochemical and biological preparations for medical purposes, namely, diagnostic and detection reagents for medical use; in vitro diagnostic reagents for medical use; histology and cytology reagents and staining dyes for preparation and staining of tissue specimens for medical purposes; diagnostic reagents for medical use in the fields of pathology, immunohistochemistry and in situ-hybridization Scientific apparatus, equipment and instruments for performing analyses in laboratories, namely, automated slide staining apparatus for treating and staining tissue slide specimens for laboratory or research use; laboratory equipment, namely, automated sample handling equipment for treating and staining tissue slide specimens for diagnostic use for laboratory or research use; automated laboratory instruments, namely, slide scanners, digital imaging apparatus, microscopes and computer systems comprised of computer hardware and downloadable computer software, all for staining and visualization of tissue or cell based samples for research and scientific use; downloadable computer software for medical and diagnostic purposes, namely, for diagnosing medical disorders; downloadable computer software for the provision of automated diagnostic laboratory processes; downloadable computer software for use with laboratory instruments, namely, for use in providing remote automated control, connection, data analysis, and data management; computer systems comprised of computer hardware and downloadable software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposes; downloadable bioinformatics-enabled medical diagnosis software Medical apparatus and instruments for medical purposes, namely, automated slide staining apparatus for treating and staining tissue specimens for cancer and other tissue-based medical diagnostic testing; diagnostic apparatus for medical purposes, namely, sample preparation device for cancer and other tissue-based medical diagnostic testing; medical apparatus for performing in-vitro diagnostic tests for cancer and other tissue-based diseases; automated slide preparation and staining apparatus for use with tissue slide specimens for medical diagnostic use; medical apparatus and instruments for performing histological and cytological tissue processing and staining for diagnostic purposes
A test carrier system (182) is disclosed. The test carrier system (182) comprises: at least one reaction and measurement cup (184), wherein the reaction and measurement cup (184) is configured for receiving at least one buffer solution (186), wherein the reaction and measurement cup (184) comprises at least one optical window (190) which is received in at least one wall (192) of the reaction and measurement cup (184), the optical window (192) enabling optical analysis of the buffer solution (186); and at least one sample processing unit (110), wherein the sample processing unit (110) is attachable to the reaction and measurement cup (184), wherein the sample processing unit (110) comprises: at least one sample application area (112), wherein the sample application area (112) is configured for receiving at least one sample, wherein the sample application area (112) comprises at least one capillary (114) which opens into an interior space (116) of the sample processing unit (110); and at least one chemical reagent (194), wherein the chemical reagent is received within the interior space (116) of the sample processing unit (110) or within the reaction and measurement cup (184); wherein the test carrier system (182) is configured to be rotatable around a rotation axis (196) of the test carrier system (182) whereby the buffer solution (186) is alternatively transportable to the sample application area (112) or to the chemical reagent (194) depending on at least one of a direction of rotation and a degree of rotation of the test carrier system (182) around the rotation axis (196) of the test carrier system (182).
In a first aspect, the invention relates to a filter element, preferably a blood filter element, comprising (A) a porous film, wherein the porous film comprises at least one film forming polymer and at least one film opener and is free of reactive agents; and (B) a porous support. A second aspect of the invention is directed to a process for preparing a filter element according to the first aspect. In a third aspect, the invention relates to a filter assembly, comprising (I) the filter element of the first aspect; and (II) a spreading member (C). A fourth aspect of the invention is directed to the filter element of the first aspect or the filter assembly of the third aspect, being prepared in the form of a sheet or stripe, preferably cuttable and/or punchable sheet or stripe, from which the filter element or the filter assembly is cut and/or punched in required dimensions, wherein the sheet or stripe has larger dimensions regarding length and width than the filter element or the filter assembly, allowing to cut and/or punch out at least one filter element or filter assembly, wherein in case of a filter assembly, the remaining part of spreading member (C) is optionally removed after cutting and/or punching. A fifth aspect of the invention is related to a method for preparing a filter element of the first aspect or the filter assembly of the third aspect. A sixth aspect of the invention relates to a test carrier system comprising the filter element of the first aspect, and a seventh aspect of the invention is related to a plasma separation and metering unit comprising the filter element of the first aspect. An eight aspect of the invention is directed to the use of the filter element of the first aspect or the plasma separation and metering unit of the seventh aspect for separation of blood plasma from whole blood.
B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
A plasma separation and metering unit (110) is disclosed. The plasma separation and metering unit (110) comprises: • at least one housing (112), wherein the housing (112) comprises at least one receptacle (114) forming at least one sample port (116) for receiving at least one biological sample (168) comprising plasma (174); • at least one plasma separation element (118), wherein the plasma separation element (118) is received in the receptacle (114) of the housing (112), wherein the plasma separation element (118) comprises a sample application side (120) facing the sample port (116) and a plasma side (122) opposing the sample application side (120); and • at least one plasma metering capillary (124) extending from the housing (112), wherein an application end (126) of the plasma metering capillary (124) is fluidically connected to the plasma side (122) of the plasma separation element (118) and is configured for receiving the plasma separated from the biological sample (168) by the plasma separation element (118), wherein an outlet end (128) opposing the application end (126) of the plasma metering capillary (124) comprises an outlet opening (130), and wherein the plasma metering capillary (124) further comprises at least one lateral opening (148) in a capillary wall (132), the lateral opening (148) being located adjacent to the outlet end (128).
The present invention relates to lyo-ready biocompatible solutions and lyophilisates comprising an activeRNaseInh(-SH)n, kits comprising solutions and/or lyophilisates of the present invention and methods of producing solutions and/or lyophilisates of the present invention. The present invention further relates to the use of the herein disclosed solutions, kits and/or lyophilisates for inhibiting an RNase.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Chemical preparations for scientific purposes, other than for medical or veterinary use; diagnostic preparations for research laboratory use; diagnostic reagents for scientific or research use; chemical reagents for use in genetic research; chemical preparations for use in DNA analysis [other than medical]; biomolecule labeling kits comprising reagents for use in scientific research; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; calibration fluids for medical apparatus; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) [other than for medical or veterinary purposes].
(2) In vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for use in medical genetic testing; reagents for in-vitro laboratory use [for medical purposes]; chemical preparations for use in DNA analysis [medical]; preparations for detecting genetic predispositions for medical purposes; nucleic acid sequences for medical and veterinary purposes.
(3) Scientific apparatus and instruments; laboratory instruments [other than for medical use]; instruments for diagnosis [for scientific use]; quantitative polymerase chain reaction [PCR] instruments for scientific use; real-time polymerase chain reaction [PCR] instruments for scientific use; laboratory devices for detecting genetic sequences; diagnostic apparatus for research laboratory use; DNA microarray; devices for analyzing genome information; devices for analyzing protein sequence used as laboratory apparatus; research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; nucleic acid sequencers for scientific purposes; laboratory devices for detecting genetic sequences; gene amplifiers; computer software for use in medical decision support systems; workflow management system software; bioinformatics software.
(4) Testing apparatus for medical purposes; diagnostic apparatus for medical purposes; real-time polymerase chain reaction [PCR] instruments for medical use; diagnostic testing instruments for use in immunoassay procedure [medical]; immunochemical medical diagnostic testing apparatus for detecting and measuring antibody levels; apparatus for DNA and RNA testing for medical purposes; apparatus for analysing substances [for medical use]; diagnostic apparatus for medical purposes used in medical laboratories; genetic testing apparatus for medical purposes. (1) Research in the field of DNA mutation; DNA screening for scientific research purposes; laboratory research in the field of gene expression; consultancy relating to laboratory testing; medical research; research and development in the field of diagnostic preparations; providing temporary use of on-line non-downloadable operating software for accessing and using a cloud computing network; information on the subject of scientific research in the field of biochemistry and biotechnology; software as a service [SaaS].
